Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-22 pm EDT 		Pre-market 07:59:47 am
219 USD -1.12% Intraday chart for Charles River Laboratories International, Inc. 221.2 +1.01%
May. 15 Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM
May. 13 TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,416 12,366 18,969 11,086 12,127 11,281 - -
Enterprise Value (EV) 1 9,066 14,117 21,394 13,564 14,497 13,226 12,739 12,195
P/E ratio 29.9 x 34.5 x 49.5 x 23 x 25.6 x 27.7 x 22.4 x 18.6 x
Yield - - - - - - - -
Capitalization / Revenue 2.83 x 4.23 x 5.36 x 2.79 x 2.94 x 2.67 x 2.49 x 2.32 x
EV / Revenue 3.46 x 4.83 x 6.04 x 3.41 x 3.51 x 3.13 x 2.81 x 2.51 x
EV / EBITDA 15 x 20.1 x 24.3 x 13.7 x 14.3 x 12.5 x 10.9 x 9.5 x
EV / FCF 26.6 x 37.1 x 40.2 x 46 x 39.7 x 29.7 x 22.2 x 19 x
FCF Yield 3.75% 2.69% 2.49% 2.17% 2.52% 3.36% 4.5% 5.26%
Price to Book 4.55 x 5.85 x 7.46 x 3.73 x 3.37 x 2.78 x 2.43 x 2.12 x
Nbr of stocks (in thousands) 48,839 49,743 50,464 50,879 51,297 51,512 - -
Reference price 2 151.8 248.6 375.9 217.9 236.4 219.0 219.0 219.0
Announcement Date 2/11/20 2/17/21 2/16/22 2/22/23 2/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,621 2,924 3,540 3,976 4,129 4,221 4,529 4,866
EBITDA 1 604.4 701.3 879.5 990.9 1,013 1,062 1,170 1,283
EBIT 1 497.2 585 742.1 834 838.8 874.3 976.1 1,071
Operating Margin 18.97% 20.01% 20.96% 20.97% 20.31% 20.71% 21.55% 22.01%
Earnings before Tax (EBT) 1 304.1 447.1 480.7 623 581.3 533.8 688.9 821.5
Net income 1 252 364.3 391 486.2 474.6 406.4 512.7 608.8
Net margin 9.61% 12.46% 11.04% 12.23% 11.49% 9.63% 11.32% 12.51%
EPS 2 5.070 7.200 7.600 9.480 9.220 7.910 9.770 11.76
Free Cash Flow 1 340.4 380 532 294.9 365.4 444.8 572.6 641.3
FCF margin 12.99% 13% 15.03% 7.42% 8.85% 10.54% 12.64% 13.18%
FCF Conversion (EBITDA) 56.32% 54.19% 60.5% 29.76% 36.06% 41.88% 48.93% 49.98%
FCF Conversion (Net income) 135.08% 104.31% 136.07% 60.65% 76.98% 109.46% 111.69% 105.33%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/11/20 2/17/21 2/16/22 2/22/23 2/14/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 905 913.9 973.1 989.2 1,100 1,029 1,060 1,027 1,013 1,012 1,023 1,069 1,114 1,088 1,103
EBITDA 1 226.9 233.2 250.4 240.4 266.9 259.8 259.5 255.4 238.5 233.1 243.6 283.4 304.1 263 272.7
EBIT 1 189.1 196 211.7 201.4 224.8 217.8 216.2 210.9 193.9 187.4 197 235.5 254.2 223.8 233
Operating Margin 20.89% 21.45% 21.75% 20.36% 20.44% 21.16% 20.4% 20.54% 19.14% 18.53% 19.25% 22.03% 22.82% 20.58% 21.12%
Earnings before Tax (EBT) 1 163.6 110.8 144.1 123.1 244.9 131 128.7 112.9 208.7 99.01 110.2 156 168.6 149.8 156.9
Net income 1 137.6 93.02 109.3 96.47 187.4 103.1 97.02 87.39 187.1 67.33 89.36 115.3 131 109.2 118.7
Net margin 15.2% 10.18% 11.23% 9.75% 17.04% 10.02% 9.15% 8.51% 18.46% 6.66% 8.73% 10.79% 11.76% 10.04% 10.76%
EPS 2 2.670 1.810 2.130 1.880 3.650 2.010 1.890 1.690 3.620 1.300 1.727 2.253 2.563 2.080 2.260
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/16/22 5/4/22 8/3/22 11/2/22 2/22/23 5/11/23 8/9/23 11/8/23 2/14/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,650 1,751 2,425 2,477 2,370 1,945 1,458 914
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.73 x 2.497 x 2.758 x 2.5 x 2.339 x 1.831 x 1.245 x 0.7126 x
Free Cash Flow 1 340 380 532 295 365 445 573 641
ROE (net income / shareholders' equity) 22.7% 22% 22.8% 20.7% 16.7% 14.8% 14.5% 14.1%
ROA (Net income/ Total Assets) 7.82% 8.08% 8.48% 7.8% 6.95% 7.96% 7.75% 8.3%
Assets 1 3,222 4,508 4,612 6,232 6,830 5,104 6,613 7,336
Book Value Per Share 2 33.40 42.50 50.40 58.40 70.10 78.80 90.20 103.0
Cash Flow per Share 2 9.680 10.80 15.10 12.10 13.30 15.40 16.70 18.50
Capex 1 141 167 229 325 319 305 327 348
Capex / Sales 5.36% 5.7% 6.46% 8.17% 7.71% 7.23% 7.21% 7.15%
Announcement Date 2/11/20 2/17/21 2/16/22 2/22/23 2/14/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Charles River Laboratories International, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
219 USD
Average target price
265.6 USD
Spread / Average Target
+21.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-7.36% 11.28B
MODERNA, INC. Stock Moderna, Inc.
+64.23% 62.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.31% 41.18B
LONZA GROUP AG Stock Lonza Group AG
+45.55% 40.29B
CELLTRION, INC. Stock Celltrion, Inc.
-8.29% 27.9B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.97% 26.21B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.16% 19.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+7.54% 13.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.72% 12.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.17% 12.05B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. Financials Charles River Laboratories International, Inc.